文献速递主动脉疾病血液透析通路

复杂腹主动脉及胸腹主动脉动脉瘤开窗分支腔内修复术中髂股导管的结局

Outcomes of iliofemoral conduits during fenestrated-branched endovascular repair of complex abdominal and thoracoabdominal aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2022-11-05

该研究回顾性分析了2013至2021年466例接受开窗分支腔内修复术(FB-EVAR)的复杂腹主动脉瘤(CAAA)和胸腹主动脉瘤(TAAA)患者,评估髂股导管的技术要点与结局。7.5%患者需要髂股导管,女性、慢性阻塞性肺疾病、外周动脉疾病及美国麻醉医师协会分级III级或以上者使用更频繁。分期手术与较短手术时间、较少失血和较低输血需求相关。

要点

  • 466例FB-EVAR患者中35例(7.5%)需要髂股导管,2013-2017年24例(10.4%)vs 2018-2021年11例(4.7%)(P = .019)。
  • 髂股导管在I-III型TAAA中占12%,IV型TAAA中占6%,CAAA中占3%(P = .009)。
  • 本次FB-EVAR中经腹膜后暴露的髂股导管与更长手术时间、更高估计失血量和输血率及更低技术成功率相关。

核心结论

  • 选择性使用髂股导管的FB-EVAR是安全的,死亡率低,未发生意外髂动脉破裂或中转开放手术。
  • 分期方法与本次手术中较短手术时间、较少失血和较低输血需求相关。

研究设计与样本

  • 回顾性分析了先前前瞻性非随机研究中的466例连续患者,研究FB-EVAR治疗CAAA/TAAA(2013-2021)。
  • 髂股导管通过开放手术技术(临时或永久)在髂内动脉通畅的患者中实施,或在髂内动脉闭塞的患者中采用血管腔内技术。
  • 终点在有任何髂导管或无导管的患者中评估,以及在本次FB-EVAR之前或期间实施导管的患者中评估,包括手术指标、技术成功率和主要不良事件(MAE)。

主要发现

  • 共治疗138例CAAA、141例IV型TAAA和187例I-III型TAAA,平均每例患者纳入3.89 ± 0.52根血管。
  • 任何髂导管需要35例(7.5%),包括2013至2017年治疗的24例(10.4%)和2018至2021年手术的11例(4.7%)(P = .019)。
  • 19例患者使用永久导管行髂股旁路,11例使用临时髂导管,5例使用腔内导管。
  • 髂股导管在I至III型TAAA患者中占12%,IV型TAAA中占6%,CAAA中占3%(P = .009)。
  • 女性(74% vs 27%;P < .001)、慢性阻塞性肺疾病(49% vs 28%;P = .013)、外周动脉疾病(31% vs 15%;P = .009)和美国麻醉医师协会分级III级或以上(74% vs 51%;P = .009)的患者中使用髂股导管更频繁。

关键数值与推荐

  • 整个研究中无意外髂动脉破裂。
  • 所有患者30天死亡率为1%,MAE为19%。
  • 本次FB-EVAR中经腹膜后暴露的髂股导管与无腹膜后暴露的髂股导管及无髂股导管的对照患者相比,手术时间更长(322 ± 97分钟 vs 323 ± 110分钟 vs 215 ± 90分钟;P < .001),估计失血量更高(425 ± 620 mL vs 580 ± 1050 mL vs 250 ± 400 mL;P < .001),红细胞输血率更高(92% vs 78% vs 32%;P < .001),技术成功率更低(83% vs 87% vs 98%;P < .001),但术中入路并发症和MAE无差异。
  • 三组间死亡率或其他特定MAE无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the technical pitfalls and outcomes of iliofemoral conduits during fenestrated-branched endovascular repair (FB-EVAR) of complex abdominal aortic aneurysms (CAAAs) and thoracoabdominal aortic aneurysms (TAAAs). METHODS: We retrospectively reviewed the clinical data of 466 consecutive patients enrolled in a previous prospective nonrandomized study to investigate FB-EVAR for CAAAs/TAAAs (2013-2021). Iliofemoral conduits were performed through open surgical technique (temporary or permanent) in patients with patent internal iliac arteries or endovascular technique among those with occluded internal iliac arteries. End points were assessed in patients who had any iliac conduit or no conduits, and in patients who had conduits performed prior or during the index FB-EVAR, including procedural metrics, technical success, and major adverse events (MAE). RESULTS: There were 138 CAAAs, 141 extent IV, and 187 extent I-III TAAAs treated by FB-EVAR with an average of 3.89 ± 0.52 vessels incorporated per patient. Any iliac conduit was required in 35 patients (7.5%), including 24 patients (10.4%) treated between 2013 and 2017 and 11 (4.7%) who had procedures between 2018 and 2021 (P = .019). Nineteen patients had permanent conduits using iliofemoral bypass, 11 had temporary iliac conduits, and 5 had endoconduits. Iliofemoral conduits were necessary in 12% of patients with extent I to III TAAA, in 6% with extent IV TAAA, and in 3% with CAAA (P = .009). The use of iliofemoral conduit was more frequent among women (74% vs 27%; P < .001) and in patients with chronic obstructive pulmonary disease (49% vs 28%; P = .013), peripheral artery disease (31% vs 15%; P = .009), and American Society of Anesthesiologists classification of III or higher (74% vs 51%; P = .009). There were no inadvertent iliac artery disruptions in the entire study. The 30-day mortality and MAE were 1% and 19%, respectively, for all patients. An iliofemoral conduit using retroperitoneal exposure during the index FB-EVAR was associated with longer operative time (322 ± 97 minutes vs 323 ± 110 minutes vs 215 ± 90 minutes; P < .001), higher estimated blood loss (425 ± 620 mL vs 580 ± 1050 mL vs 250 ± 400 mL; P < .001), and rate of red blood transfusion (92% vs 78% vs 32%; P < .001) and lower technical success (83% vs 87% vs 98%; P < .001), but no difference in intraoperative access complications and MAEs, compared with iliofemoral conduits without retroperitoneal exposure during the index FB-EVAR and control patients who had FB-EVAR without iliofemoral conduits, respectively. There were no differences in mortality or in other specific MAE among the three groups. CONCLUSIONS: FB-EVAR with selective use of iliofemoral conduits was safe with low mortality and no occurrence of inadvertent iliac artery disruption or conversion. A staged approach is associated with shorter operating time, less blood loss, and lower transfusion requirements in the index procedure.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Dias-Neto M, Marcondes G, Tenorio ER, et al. Outcomes of iliofemoral conduits during fenestrated-branched endovascular repair of complex abdominal and thoracoabdominal aortic aneurysms. J Vasc Surg. 2022. PMID: 36343871. doi:10.1016/j.jvs.2022.10.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。